8 citations
,
November 2018 in “BMC Pulmonary Medicine” This case report describes the first instance of ANCA positive vasculitis secondary to Mycobacterium abscessus pulmonary disease, highlighting the complex interplay of immune dysfunction and treatment challenges.
1 citations
,
October 2025 in “Frontiers in Immunology” In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.
1 citations
,
May 2021 in “Mayo Clinic Proceedings” This medical case report describes a 69-year-old man's diagnosis and management of ANCA-associated vasculitis leading to rapidly progressive glomerulonephritis, ultimately treated with glucocorticoids and rituximab.
5 citations
,
January 2016 in “Journal of The American Academy of Dermatology” This review discusses inflammatory and medication-related nephrocutaneous disease associations and emphasizes the importance of timely referral to nephrology for early management, but it reports no new clinical results.
January 2026 in “Frontiers in Immunology” This case study details a 44-year-old woman with rheumatoid arthritis and systemic lupus erythematosus who developed hypereosinophilic asthma and was initially treated as ANCA-negative eosinophilic granulomatosis with polyangiitis. Her condition, eventually classified as HASM, underscores the need for evaluating EGPA-spectrum disorders in similar scenarios.